Re-appointment of Dr.Pankaj Shah (DIN:02836324) as Managing Director & CEO subject to the members approval for a period of three (3) years i.e from August 01, 2025 to July 31, 2028

Management Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹53.25

prior close

₹54.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%+3.8% vs market

Healthcare Service Provider peers, median of 23sector+0.0%+5.0% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+2.9

30m

+2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+1.2+3.8+0.0+5.0

Next day

+10.2+0.1+10.1+0.1+10.1

+15.7+0.9+14.8+0.1+15.6

+9.9+0.8+9.1-0.7+10.6

+4.5+1.4+3.1-0.2+4.7

+1.3+2.0-0.7+0.7+0.6

+1.4+2.3-0.9+1.1+0.3

15d

+2.3+5.2-2.8+2.6-0.2

+6.7+1.6+5.1+3.1+3.6

+3.6+7.7-4.1+4.5-0.9

+16.3+4.0+12.3+8.9+7.4

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Directors of Aspira Pathlab & Diagnostics, at its meeting on May 16, 2025, approved the re-appointment of Dr. Pankaj Shah (DIN: 02836324) as Managing Director & CEO for a fresh term of three years, from August 01, 2025 to July 31, 2028. His current term is expiring on July 31, 2025, and the re-appointment is subject to shareholder approval. Dr. Shah has over 43 years of experience in pathology and has been with the company as its guiding force. He is not related to any other Director or KMP and is not debarred from holding office by any regulator.

Likely market impact

This is a continuity announcement — Dr. Shah remains at the helm, providing leadership stability. No material change in strategy or governance is expected, and the stock price is unlikely to move meaningfully on this news.